Hi, this is Warren Alney. Thanks so much for listening to this podcast of To the Point,

and I want to tell you about another podcast that's available here at KCRW,

and that's the program, DNA, hosted by Francis Anderton.

Francis is well connected in the industry of design and architecture and art.

She used to be editor of an architecture magazine.

She knows the trends before they happen. She'll be able to fill you in on them. You can find DNA on KCRW's iTunes page.

From KCRW in Santa Monica and PRI, Public Radio International, this is To the Point.

Iran's nuclear program, once again, it's down to the wire.

Hello again, I'm Armin Alney, and this is To the Point from Public Radio International.

A daily look at the issues Americans care about most.

There's only a week remaining for talks to continue a one-year

limit on Iran's nuclear program in exchange for relaxing, crippling economic sanctions.

Russia, Israel, Saudi Arabia, and Western Europe all have major stakes in the outcome

which could reshape the political contours of the Middle East. President Obama and Iran's

President Rouhani both want an agreement, but Republicans could

pass new sanctions or the Supreme Leader could kill any deal.

We'll hear about possible benefits, potential risks, and political consequences.

Today's talking point is Truvada's success in preventing the spread of AIDS, inspiring overconfidence.

First, here's the news.

Listen to KCRW's 24-hour all-news channel.

Stream BBC World Service, NPR and KCRW programs.

Continuous coverage and accessible via our smartphone app or online at kCRw.com.

...